Kennedy Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Kennedy Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,418	Closed	-$226K	–	691
2024 Q4	$226K	Sell	13,418 -81,131	-86%	-$1.56M	0.01%	656
2024 Q3	$1.53M	Buy	94,549 +4,615	+5%	+$54.3K	0.03%	548
2024 Q2	$739K	Buy	+89,934	New	+$941K	0.02%	609
2014 Q3	–	Sell	-4,878	Closed	-$177K	–	777
2014 Q2	$177K	Sell	4,878 -53,370	-92%	-$1.81M	﹤0.01%	735
2014 Q1	$2.26M	Buy	58,248 +15,947	+38%	+$568K	0.04%	518
2013 Q4	$1.21M	Buy	42,301 +16,397	+63%	+$481K	0.02%	631
2013 Q3	$927K	Buy	+25,904	New	+$945K	0.02%	644

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CLGM

Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kennedy Capital Management's RIGL Position: Q1 2025 in Review

Kennedy Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2025, closing a stake of 13,418 shares — an estimated $226K sold.

Kennedy Capital Management first reported a position in RIGL in Q3 2013 and held it in 7 quarters. The position peaked at $2.26M in Q1 2014. 123 funds tracked by Wall St. Rank hold RIGL as of Q1 2025.

Kennedy Capital Management reported no remaining Rigel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Kennedy Capital Management sold 13,418 Rigel Pharmaceuticals shares in Q1 2025, an estimated $226K.
Kennedy Capital Management first reported a position in Rigel Pharmaceuticals in Q3 2013 and held it in 7 quarters.
Kennedy Capital Management's Rigel Pharmaceuticals position peaked at $2.26M in Q1 2014.
123 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2025.

Based on Kennedy Capital Management's 13F filing for Q1 2025, filed 13 May 2025.